Log In
BCIQ
Print this Print this
 

CNTX-4975

  Manage Alerts
Collapse Summary General Information
Company Centrexion Therapeutics Corp.
DescriptionInjectable, synthetic capsaicin targeting transient receptor potential vanilloid 1 (TRPV1; VR1)
Molecular Target Transient receptor potential vanilloid 1 (TRPV1) (VR1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat moderate to severe osteoarthritis (OA) knee pain; Treat painful intermetatarsal neuroma (Morton's neuroma)
Regulatory Designation U.S. - Fast Track (Treat painful intermetatarsal neuroma (Morton's neuroma));
U.S. - Orphan Drug (Treat painful intermetatarsal neuroma (Morton's neuroma))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today